What is a stock summary page? Click here for an overview.
Business Description
Genmab AS
ISIN : DK0010272202
Share Class Description:
LTS:0MGB: Ordinary SharesCompare
Compare
Traded in other countries / regions
GMAB.DenmarkGMAB.USA0MGB.UKGMAB.MexicoGE91.GermanyGMAB.Austria IPO Date
2010-04-01Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.51 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.11 | |||||
| Interest Coverage | 70.68 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.67 | |||||
| Beneish M-Score | 6.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 37.7 | |||||
| 3-Year EBITDA Growth Rate | 33.3 | |||||
| 3-Year EPS without NRI Growth Rate | 42.8 | |||||
| 3-Year FCF Growth Rate | 56.9 | |||||
| 3-Year Book Growth Rate | 19.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 13.96 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.14 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.62 | |||||
| 9-Day RSI | 35.74 | |||||
| 14-Day RSI | 35.92 | |||||
| 3-1 Month Momentum % | 3.78 | |||||
| 6-1 Month Momentum % | 3.38 | |||||
| 12-1 Month Momentum % | -19.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.25 | |||||
| Quick Ratio | 5.24 | |||||
| Cash Ratio | 3.98 | |||||
| Days Inventory | 24.61 | |||||
| Days Sales Outstanding | 97.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.1 | |||||
| Shareholder Yield % | 4.62 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.42 | |||||
| Operating Margin % | 32.18 | |||||
| Net Margin % | 36.44 | |||||
| FCF Margin % | 34.69 | |||||
| ROE % | 23.96 | |||||
| ROA % | 20 | |||||
| ROIC % | 45.39 | |||||
| 3-Year ROIIC % | 23.97 | |||||
| ROC (Joel Greenblatt) % | 243 | |||||
| ROCE % | 26.23 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 10.4 | |||||
| Forward PE Ratio | 11.78 | |||||
| PE Ratio without NRI | 12.06 | |||||
| Shiller PE Ratio | 23.47 | |||||
| Price-to-Owner-Earnings | 11.68 | |||||
| PEG Ratio | 0.62 | |||||
| PS Ratio | 3.78 | |||||
| PB Ratio | 2.19 | |||||
| Price-to-Tangible-Book | 3.68 | |||||
| Price-to-Free-Cash-Flow | 10.91 | |||||
| Price-to-Operating-Cash-Flow | 10.49 | |||||
| EV-to-EBIT | 6.46 | |||||
| EV-to-Forward-EBIT | 6.78 | |||||
| EV-to-EBITDA | 6.31 | |||||
| EV-to-Forward-EBITDA | 6.28 | |||||
| EV-to-Revenue | 2.79 | |||||
| EV-to-Forward-Revenue | 2.34 | |||||
| EV-to-FCF | 7.94 | |||||
| Price-to-GF-Value | 0.33 | |||||
| Price-to-Projected-FCF | 0.85 | |||||
| Price-to-DCF (Earnings Based) | 0.32 | |||||
| Price-to-DCF (FCF Based) | 0.29 | |||||
| Price-to-Median-PS-Value | 0.16 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.12 | |||||
| Price-to-Graham-Number | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 4.28 | |||||
| Price-to-Net-Cash | 6.69 | |||||
| Earnings Yield (Greenblatt) % | 15.48 | |||||
| FCF Yield % | 9.34 | |||||
| Forward Rate of Return (Yacktman) % | 16.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genmab AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 21,526 | ||
| EPS (TTM) (kr) | 121.33 | ||
| Beta | 1.3 | ||
| 3-Year Sharpe Ratio | -0.59 | ||
| 3-Year Sortino Ratio | -0.75 | ||
| Volatility % | 31.83 | ||
| 14-Day RSI | 35.92 | ||
| 14-Day ATR (kr) | 53.511853 | ||
| 20-Day SMA (kr) | 1341.875 | ||
| 12-1 Month Momentum % | -19.72 | ||
| 52-Week Range (kr) | 1168.5 - 2123 | ||
| Shares Outstanding (Mil) | 63.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genmab AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genmab AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genmab AS Frequently Asked Questions
What is Genmab AS(LTS:0MGB)'s stock price today?
The current price of LTS:0MGB is kr1268.25. The 52 week high of LTS:0MGB is kr2123.00 and 52 week low is kr1168.50.
When is next earnings date of Genmab AS(LTS:0MGB)?
The next earnings date of Genmab AS(LTS:0MGB) is 2025-05-08.
Does Genmab AS(LTS:0MGB) pay dividends? If so, how much?
Genmab AS(LTS:0MGB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers